Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but it's expensive.
The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive ...
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...
A chocolate recall was recently upgraded to warn consumers of a potential to “cause serious adverse health consequences of death.” ...
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults. “Today’s approval is an ...
The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.